Botanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says

MT Newswires Live

4小時前

The launch of Botanix Pharmaceuticals' (ASX:BOT) topical gel, Sofdra, performed "exceptionally well" across multiple benchmarks, Euroz Hartleys said in a note on Wednesday.

Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.

Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.

Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.

The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2568944090"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568944090\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568944090?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-18 12:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568944090","market":"us","top_or_hot":-1,"title":"Botanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says","media":"MT Newswires Live","content":"<html><body><p> The launch of <a href=\"https://laohu8.com/S/BOT.AU\">Botanix Pharmaceuticals</a>' (ASX:BOT) topical gel, Sofdra, performed \"exceptionally well\" across multiple benchmarks, <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys said in a note on Wednesday.</p><p>Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.</p><p>Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.</p><p>Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.</p><p>The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Botanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBotanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-18 12:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> The launch of <a href=\"https://laohu8.com/S/BOT.AU\">Botanix Pharmaceuticals</a>' (ASX:BOT) topical gel, Sofdra, performed \"exceptionally well\" across multiple benchmarks, <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys said in a note on Wednesday.</p><p>Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.</p><p>Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.</p><p>Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.</p><p>The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BOT.AU","symbol_name":"BOTANIX PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568944090","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568944090","pubTimestamp":1758168019,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"The launch of Botanix Pharmaceuticals'  topical gel, Sofdra, performed \"exceptionally well\" across multiple benchmarks, Euroz Hartleys said in a note on Wednesday.Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BOT.AU":"BOTANIX PHARMACEUTICALS LTD","BK7508":"医药生物股","BK7502":"大麻概念","BK7096":"制药"},"translate_title":"Euroz Hartleys表示，Botanix Pharmaceuticals推出的外用凝胶表现“非常好”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BOT.AU":1},"content_text":"The launch of Botanix Pharmaceuticals' (ASX:BOT) topical gel, Sofdra, performed \"exceptionally well\" across multiple benchmarks, Euroz Hartleys said in a note on Wednesday.Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}